Ube Industries, Santen Pharmaceutical to Co-develop Rho-kinase Inhibitor for Glaucoma and Ocular Hypertension Treatment.Tokyo, Japan, May 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - On May 9, Ube Industries and Santen Pharmaceutical jointly announced that they have basically agreed to develop DE- de- word element [L.], down; from; sometimes negative or privative, and often intensive. de- pref. 1. Do or make the opposite of; reverse: decomposition. 2. 104, a compound that inhibits the activity of Rho-kinase (ROCK). Through collaboration, the two companies aim to develop an ophthalmic solution ophthalmic solution n. A sterile solution that is free from foreign particles and is compounded and dispensed for eyedrops. for treating glaucoma and ocular hypertension. ROCK is an enzyme that phosphorylates cytoskeletal cy`to`skel´e`tal a. 1. (Cell Biology) Of or pertaining to the cytoskeleton; as, cytoskeletal microtubules s>. regulatory proteins and plays a role in cytoskeletal regulation. Details of the collaboration project will be discussed and determined. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion